Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from … [Read more…]

Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission

PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Ipsen is seeking approval of palovarotene, an oral, selective … [Read more…]

Now Health International appoints Matt Pinckard to head up Singapore growth plans

SINGAPORE–(BUSINESS WIRE)–Now Health International, the award-winning international private medical insurance (IPMI) provider, has appointed Matt Pinckard as General Manager of its Singapore operations to lead the company’s business in the region. Reporting into Rob McIntyre, Now Health International’s Chief Distribution Officer, Pinckard will lead the company’s drive to introduce new innovations and technologies in the … [Read more…]

CivaTech Oncology selected to present at BIO International Conference

SAN DIEGO–(BUSINESS WIRE)–CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California. BIO International connects top research and early stage innovations with industry and investors. CivaTech Oncology’s CivaSheet® was supported in development and in … [Read more…]

Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration

Strategic Partnership Includes Development of New Facility, Enhanced Service for Global Clinical Trials BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development … [Read more…]

Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference

SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in the virtual H.C. Wainwright Preclinical Cancer Drug Discover: Emerging Targets … [Read more…]

Invacare Corporation to Participate in the 22nd Annual CJS Securities New Ideas Summer Conference

ELYRIA, Ohio–(BUSINESS WIRE)–Matt Monaghan, chairman, president and chief executive officer of Invacare Corporation (NYSE: IVC); Kathy Leneghan, senior vice president and chief financial officer; and Lois Lee, director, treasury, investor relations and corporate communications, will participate in the 22nd Annual New Ideas Summer Conference on Tuesday, July 12, 2022. The company’s management team will be … [Read more…]

National Nonprofit, All Clear Foundation Offers Emergency Responder Mental Health Training Curriculum with Support from FirstNet, Built with AT&T in Erie, PA

DENVER–(BUSINESS WIRE)–All Clear Foundation is a national nonprofit dedicated to supporting the wellbeing of the Emergency Responder community. The cumulative stress and trauma of Response work, whether in the field or medical setting, can erode a Responder’s health, wellness, and relationships. Many, unfortunately, experience a decreased personal quality of life as a consequence of the … [Read more…]

4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq

LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that in accordance with Listing Rules 5101, … [Read more…]

Global NGS Automation Market Report to 2029 – Featuring Agilent Technologies, Danaher and Eppendorf AG Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “NGS Automation Market By Product, Sequencing Type, Application, End User – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022-2029 to reach $1.33 billion by 2029. Following a comprehensive primary and secondary study and an in-depth … [Read more…]